药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
3,7,11,15-tetramethyl-hexadecan-1-ol
Emibetuzumab
The risk or severity of adverse effects can be increased when Emibetuzumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Dalotuzumab
The risk or severity of adverse effects can be increased when Dalotuzumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Guselkumab
The risk or severity of adverse effects can be increased when Guselkumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Lampalizumab
The risk or severity of adverse effects can be increased when Lampalizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Sirukumab
The risk or severity of adverse effects can be increased when Sirukumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Brodalumab
The risk or severity of adverse effects can be increased when Brodalumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Tremelimumab
The risk or severity of adverse effects can be increased when Tremelimumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Sarilumab
The risk or severity of adverse effects can be increased when Sarilumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Solanezumab
The risk or severity of adverse effects can be increased when Solanezumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Onartuzumab
The risk or severity of adverse effects can be increased when Onartuzumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Depatuxizumab mafodotin
The risk or severity of adverse effects can be increased when Depatuxizumab mafodotin is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Bapineuzumab
The risk or severity of adverse effects can be increased when Bapineuzumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Durvalumab
The risk or severity of adverse effects can be increased when Durvalumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Figitumumab
The risk or severity of adverse effects can be increased when Figitumumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Ficlatuzumab
The risk or severity of adverse effects can be increased when Ficlatuzumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Tabalumab
The risk or severity of adverse effects can be increased when Tabalumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Conatumumab
The risk or severity of adverse effects can be increased when Conatumumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Human Varicella-Zoster Immune Globulin
The risk or severity of adverse effects can be increased when Human Varicella-Zoster Immune Globulin is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Eftrenonacog alfa
The risk or severity of adverse effects can be increased when Eftrenonacog alfa is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Tetanus Immune Globulin
The risk or severity of adverse effects can be increased when Tetanus Immune Globulin is combined with Belantamab mafodotin.